Doxycycline as an Alternative to Azithromycin in Elderly Patients

Malek, Alexandre; Granwehr, Bruno

doi:10.1016/j.ijantimicag.2020.106168

Cited by 9 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The described patients suffered from lung cancer or sarcoidosis. Malek et al 10 also mention the possible role of doxycycline in COVID-19 therapy in combination with hydroxychloroquine instead of azithromycin. Administration of hydroxychloroquine with azithromycin causes viral remission in 100% of patients on the 5th day of therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Administration of hydroxychloroquine with azithromycin causes viral remission in 100% of patients on the 5th day of therapy. 13 Treatment with azithromycin is associated with cardiotoxicity for the elderly; therefore, Malek et al 10 suggest switching to doxycycline primarily in elderly patients. Yasemin Cag et al, 11 also draw attention to the success of the use of doxycycline in the therapy of dengue haemorrhagic fever, while negating the effectiveness of lopinavir in the treatment of COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

“…It is difficult to unequivocally confirm the effectiveness of the medication in the presented cases, but similar observations were made by other researchers. 3,[9][10][11][12] In the study of Mohammud M. Alam et al, 9 a description of a series of 89 elderly patients with confirmed moderate to severe COVID-19 with concomitant diseases was presented. All patients in this group were treated with doxycycline for 7 days at a dose of 100 mg daily.…”

Section: Discussionmentioning

confidence: 99%

“… 5 It has been well proven to block a cytokine storm. Malek et al 8 , 10 in their publications highlighted the important role of doxycycline in the treatment of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Doxycycline in the Coronavirus Disease 2019 Therapy

Dorobisz¹,

Dorobisz²,

Janczak³

et al. 2021

TCRM

View full text Add to dashboard Cite

Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus disease 2019 (COVID-19) treated with doxycycline with significant improvement have been discussed. Doxycycline is a known antibiotic, but also an anti-inflammatory and immunomodulatory drug, so it seems to be ideal for the treatment of COVID-19. Doxycycline, as an easily available and low-cost medication, should be considered as a COVID-19 therapy in all patients in the first days of the symptoms of a SARS-CoV-2 infection. Due to its immunomodulatory, anti-inflammatory, cardioprotective and antiviral effects, it seems to be an ideal drug for patients with mild, moderate and severe disease. A large multicentre study is needed to evaluate the effects of this medication.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“… 5 It has been well proven to block a cytokine storm. Malek et al 8 , 10 in their publications highlighted the important role of doxycycline in the treatment of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Doxycycline in the Coronavirus Disease 2019 Therapy

Dorobisz¹,

Dorobisz²,

Janczak³

et al. 2021

TCRM

View full text Add to dashboard Cite

show abstract

“…Antiviral effects of doxycycline Hydroxychloroquine with doxycycline seem to be a better alternative to azithromycin for the treatment of corona infection especially in geriatric patients. 19 Doxycycline and other tetracycline derivatives such as minocycline exhibit anti-inflammatory effects along with in vitro antiviral activity against several RNA viruses. 20 Use of these agents has been associated with clinical improvement, even reversal of cytokine storm in some infections caused by RNA viruses, such as dengue fever.…”

mentioning

confidence: 99%

Repurposed application of doxycycline in COVID 19 treatment

Dash¹,

Chaubey²,

Sahu³

et al. 2021

IJPCA

View full text Add to dashboard Cite

Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review

Bhowmick

Dang²,

Vallish³

et al. 2021

Drug Saf

View full text Add to dashboard Cite

Introduction and Objective Ivermectin (IVM) and doxycycline (DOXY) have demonstrated in-vitro activity against SARS-CoV-2, and have a reasonable safety profile. The objective of this systematic review was to explore the evidence in the literature on the safety and efficacy of their use as monotherapy and combination therapy in COVID-19 management. Methods After prospectively registering the study protocol with the Open Science Framework, we searched PubMed, Google Scholar, clinicaltrials.gov, various pre-print servers and reference lists for relevant records published until 16 February, 2021 using appropriate search strategies. Baseline features and data pertaining to efficacy and safety outcomes were extracted separately for IVM monotherapy, DOXY monotherapy, and IVM + DOXY combination therapy. Methodological quality was assessed based on the study design. Results Out of 200 articles screened, 19 studies (six retrospective cohort studies, seven randomised controlled trials, five non-randomised trials, one case series) with 8754 unique patients with multiple stages of COVID-19 were included; four were pre-prints and one was an unpublished clinicaltrials.gov document. The comparator was standard care and ‘hydroxychloroquine + azithromycin’ in seven and three studies respectively, and two studies were placebo controlled; six studies did not have a comparator. IVM monotherapy, DOXY monotherapy and IVM + DOXY were explored in eight, five and five studies, respectively; one study compared IVM monotherapy and IVM + DOXY with placebo. While all studies described efficacy, the safety profile was described in only six studies. Efficacy outcomes were mixed with some studies concluding in favour of the intervention and some studies displaying no significant benefit; barring one study that described 9/183 patients with erosive esophagitis and non-ulcer dyspepsia with IVM + DOXY (without causality assessment details), there were no new safety signals of concern with any of the three interventions considered. The quality of studies varied widely, with five studies having a ‘good’ methodological quality. Conclusions Evidence is not sufficiently strong to either promote or refute the efficacy of IVM, DOXY, or their combination in COVID-19 management. Systematic Review Protocol Registration Details Open Science Framework: https://osf.io/n7r2j . Supplementary Information The online version contains supplementary material available at 10.1007/s40264-021-01066-y.

show abstract

Doxycycline as an Alternative to Azithromycin in Elderly Patients

Cited by 9 publications

References 7 publications

Doxycycline in the Coronavirus Disease 2019 Therapy

Doxycycline in the Coronavirus Disease 2019 Therapy

Repurposed application of doxycycline in COVID 19 treatment

Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review

Contact Info

Product

Resources

About